Timm Bauer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1371203/publications.pdf

Version: 2024-02-01

50	1,204	17 h-index	34
papers	citations		g-index
51	51	51	2234
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Comparison of the Effectiveness of Transcatheter Aortic Valve Implantation in Patients With Stenotic Bicuspid Versus Tricuspid Aortic Valves (from the German TAVI Registry). American Journal of Cardiology, 2014, 113, 518-521.	1.6	125
2	Effect of an invasive strategy on in-hospital outcome in elderly patients with non-ST-elevation myocardial infarction. European Heart Journal, 2007, 28, 2873-2878.	2.2	124
3	Rapid Deployment Versus Conventional Bioprosthetic Valve Replacement for Aortic Stenosis. Journal of the American College of Cardiology, 2018, 71, 1417-1428.	2.8	100
4	Use and Outcomes of Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock (from the EHS-PCI Registry). American Journal of Cardiology, 2012, 109, 941-946.	1.6	84
5	Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42Â776 patients. European Journal of Cardio-thoracic Surgery, 2018, 53, 552-559.	1.4	71
6	Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina. International Journal of Cardiology, 2011, 151, 164-169.	1.7	66
7	Impact of new pacemaker implantation following surgical and transcatheter aortic valve replacement on 1-year outcome. European Journal of Cardio-thoracic Surgery, 2020, 57, 151-159.	1.4	55
8	Incidence and Clinical Impact of Stroke Complicating Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 362-369.	3.9	50
9	Gender differences in patients with acute ST-elevation myocardial infarction complicated by cardiogenic shock. Clinical Research in Cardiology, 2009, 98, 781-786.	3.3	43
10	Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 576-581.	2.8	43
11	Prima-vista multi-vessel percutaneous coronary intervention in haemodynamically stable patients with acute coronary syndromes: Analysis of over 4.400 patients in the EHS-PCI registry. International Journal of Cardiology, 2013, 166, 596-600.	1.7	29
12	Use and outcome of radial versus femoral approach for primary PCI in patients with acute ST elevation myocardial infarction without cardiogenic shock: Results from the ALKK PCI registry. Catheterization and Cardiovascular Interventions, 2015, 86, S8-14.	1.7	28
13	Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. International Journal of Cardiology, 2015, 179, 90-94.	1.7	26
14	Fate of Patients With Coronary Perforation Complicating Percutaneous Coronary Intervention (from) Tj ETQq0 0 Cardiology, 2015, 116, 1363-1367.	0 rgBT /Ov 1.6	verlock 10 Tf 25
15	Efficacy of a 24-h primary percutaneous coronary intervention service on outcome in patients with ST elevation myocardial infarction in clinical practice. Clinical Research in Cardiology, 2009, 98, 171-178.	3.3	24
16	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. Clinical Research in Cardiology, 2015, 104, 1064-1071.	3.3	21
17	A multicenter postâ€marketing evaluation of the Elixir DESolve [®] Novolimusâ€eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterization and Cardiovascular Interventions, 2018, 92, 1021-1027.	1.7	21
18	Effect of Chronic Statin Pretreatment on Hospital Outcome in Patients With Acute Non-ST-Elevation Myocardial Infarction. Journal of Cardiovascular Pharmacology, 2009, 53, 132-136.	1.9	17

#	Article	IF	CITATIONS
19	Impact of the learning curve on procedural results and acute outcome after percutaneous coronary interventions with everolimus-eluting bioresorbable scaffolds in an all-comers population. Cardiovascular Revascularization Medicine, 2015, 16, 455-460.	0.8	17
20	Prognostic Impact of Underweight (Body Mass Index <20 kg/m2) in Patients With Severe Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation or Surgical Aortic Valve Replacement (from the German Aortic Valve Registry [GARY]). American Journal of Cardiology, 2020, 129, 79-86.	1.6	17
21	Direct admission versus transfer of AMI patients for primary PCI. Clinical Research in Cardiology, 2011, 100, 217-225.	3.3	16
22	Influence of Renal Sympathetic Denervation on Cardiac Extracellular Matrix Turnover and Cardiac Fibrosis. American Journal of Hypertension, 2015, 28, 1285-1292.	2.0	15
23	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. European Respiratory Journal, 2021, 57, 1901192.	6.7	15
24	Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry Disease. PLoS ONE, 2016, 11, e0157640.	2.5	14
25	Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the Euro heart survey PCI registry. Catheterization and Cardiovascular Interventions, 2011, 78, 702-709.	1.7	13
26	Everolimus-Versus Novolimus-Eluting Bioresorbable Scaffolds for the TreatmentÂof Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 477-485.	2.9	12
27	Impact of preprocedural TIMI flow on clinical outcome in lowâ€risk patients with STâ€elevation myocardial infarction: Results from the ATLANTIC study. Catheterization and Cardiovascular Interventions, 2020, 95, 494-500.	1.7	12
28	Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 481-487.	1.8	11
29	Transcatheter or surgical aortic valve implantation in chronic dialysis patients: a German Aortic Valve Registry analysis. Clinical Research in Cardiology, 2021, 110, 357-367.	3.3	11
30	Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry. Clinical Research in Cardiology, 2011, 100, 701-709.	3.3	10
31	Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. International Journal of Cardiology, 2017, 246, 74-79.	1.7	10
32	Multivessel percutaneous coronary intervention in patients with stable angina: a common approach? Lessons learned from the EHS PCI registry. Heart and Vessels, 2012, 27, 453-459.	1.2	8
33	Implantation of everolimusâ€eluting bioresorbable scaffolds in a diabetic allâ€comers population. Catheterization and Cardiovascular Interventions, 2015, 86, 975-981.	1.7	8
34	Use and outcome of thrombus aspiration in patients with primary PCI for acute ST-elevation myocardial infarction: results from the multinational Euro Heart Survey PCI Registry. Heart and Vessels, 2016, 31, 1438-1445.	1.2	8
35	Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics. Clinical Research in Cardiology, 2010, 99, 375-383.	3.3	7
36	A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance. International Journal of Cardiology, 2016, 220, 706-710.	1.7	7

#	Article	IF	CITATIONS
37	Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions — Implications from early clinical experience during daily practice. Cardiovascular Revascularization Medicine, 2016, 17, 313-317.	0.8	6
38	Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects. Clinical Research in Cardiology, 2017, 106, 271-279.	3.3	6
39	Galectinâ€3 and ST2 as predictors of therapeutic success in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1164-1169.	1.8	6
40	Left circumflex artery-related myocardial infarction: Does ST elevation matter? Results from the Euro Heart Survey PCI registry. International Journal of Cardiology, 2013, 168, 5239-5242.	1.7	4
41	Evaluation of cystatin C and neutrophil gelatinaseâ€associated lipocalin as predictors of mortality in patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1474-1479.	1.8	4
42	Effect of Plaque Composition, Morphology, and Burden on DESolve Novolimus-Eluting Bioresorbable Vascular Scaffold Expansion and Eccentricity — An Optical Coherence Tomography Analysis. Cardiovascular Revascularization Medicine, 2019, 20, 480-484.	0.8	4
43	Incidence and outcome of peri-procedural cardiogenic shock: results from the international Euro Heart Survey PCI registry. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 120-127.	1.0	4
44	Impact of Chronic Antithrombotic Therapy on Hospital Course of Patients with Acute Myocardial Infarction. Clinical Cardiology, 2009, 32, 718-723.	1.8	3
45	Thebesian veins as drainage to the ventricle: A case report. Cardiovascular Revascularization Medicine, 2017, 18, 213-214.	0.8	2
46	Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1144-1151.	0.6	1
47	Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis. International Journal of Cardiology, 2017, 231, 73-77.	1.7	0
48	OCTâ€assessment of scaffold resorption: Analysis of strut intensity by a new resorption index for poly―l ″actic acid bioresorbable vascular scaffolds. Catheterization and Cardiovascular Interventions, 2019, 94, 928-935.	1.7	0
49	Fractional flow reserve and frequency of PCI in patients with coronary artery disease. Herz, 2020, 45, 752-758.	1.1	0
50	Fiveâ€year followâ€up of patients who underwent everolimusâ€eluting bioresorbable scaffold implantation. Catheterization and Cardiovascular Interventions, 2021, 97, 56-62.	1.7	O